Outcomes of Pharmaceutical Care Interventions in Type 2 Diabetes Mellitus Patients: A Pre-Post Pilot Study At Federal Medical Center Abakaliki, Ebonyi State, Nigeria.

Not Applicable

• Conditions: Circulatory System; Musculoskeletal Diseases; Nutritional, Metabolic, Endocrine; Kidney Disease; Cardiology; Orthopaedics

• Registration Number: PACTR202311731445746
• Lead Sponsor: Pharm. Solomon Ikechukwu Okorie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-20
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Patients with confirmed diagnosis of type 2 diabetes mellitus.
2. Patients on oral hypoglycaemic therapy for over six (6) months.
3. Patients with poor glycaemic and poor blood pressure and/ or poor lipid control.
4. Patients who the Consultant Endocrinologist of the hospital consented to their entry into the trial.
5. Patients who consented to the study by giving oral consent.

Exclusion Criteria

1. Patients with secondary forms of hypertension.
2. Patients who were pregnant
3. Patients resident outside urban settlements within the study site.
4. Patients without mobile phone numbers.
5. Patients on insulin therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycated Haemoglobin A1c (HbA1c) measured using the In2it Analyzer model 501122R.1;Drug therapy problems were identified using a stepwise approach and a specially designed data collection sheet.;Health-related quality of life is measured using the short form – 12 (SF-12) questionnaire and evaluated using the online SF-12 Health Survey Scoring Demonstration.